The company’s antibody therapy has been determined to be ineffective against the omicron variant that now dominates Covid-19 cases worldwide.
Subscribe to:
Post Comments (Atom)
< + > Real-Time Pharma Insights: Philip Poulidis on Scaling ODAIA AI – Life Sciences Today Podcast Episode 41
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Philip Poulidis, ...
No comments:
Post a Comment